Literature DB >> 20541060

ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent.

Richard M Gewanter, Kenneth E Rosenzweig, Joe Yujiao Chang, Roy Decker, Sarita Dubey, Feng-Ming Kong, Brian E Lally, Corey J Langer, Hoon Ku Lee, Benjamin Movsas.   

Abstract

The optimal strategy for the non-surgical definitive treatment of patients with good performance status non-small cell lung cancer (mostly with locally advanced disease) has dramatically evolved over time. This article presents evidence-based data to review this literature. Several decades ago, the standard treatment for most stage III inoperable NSCLC was definitive radiation therapy alone. Randomized trials have since shown superior results with sequential chemotherapy and radiation, and more recently with concurrent chemoradiation, the current standard of care. Studies suggest a limited role for induction or adjuvant systemic therapy in addition to concurrent chemoradiation. The role of altered radiation fractionation techniques, such as hyperfractionation for locally advanced disease or hypofractionation for early stage disease is also discussed. More recently, the application of more advanced radiation techniques has been explored, including intensity modulated radiation therapy (IMRT) and proton beam radiation. Finally, various case variants are presented as examples of state-of-the-art treatment approaches. Copyright 2010 American College of Radiology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541060     DOI: 10.1016/j.currproblcancer.2010.04.001

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN: 0147-0272            Impact factor:   3.187


  5 in total

1.  Non-small cell lung carcinoma in an adolescent manifested by acute paraplegia due to spinal metastases: a case report.

Authors:  Ulrike Ackert; Dieter Haffner; Carl Friedrich Classen
Journal:  J Med Case Rep       Date:  2011-09-28

Review 2.  A decade of advances in treatment of early-stage lung cancer.

Authors:  Luca Paoletti; Nicholas J Pastis; Chadrick E Denlinger; Gerard A Silvestri
Journal:  Clin Chest Med       Date:  2011-10-07       Impact factor: 2.878

Review 3.  Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).

Authors:  Victor Y Yazbeck; Liza Villaruz; Marsha Haley; Mark A Socinski
Journal:  Cancer J       Date:  2013 May-Jun       Impact factor: 3.360

4.  Stereotactic Body Radiation Therapy (SBRT) Using CyberKnife in Oligometastatic Cancer Patients; Retrospective Evaluation, Single Institution Experience.

Authors:  Abdullah Alsuhaibani; Ahmed Elashwah; Abdullah Alkafi; Camelia Constantinescus; Faisal ALzorkany
Journal:  J Gastrointest Cancer       Date:  2019-12

5.  Use of new treatment modalities for non-small cell lung cancer care in the Medicare population.

Authors:  Michael T Vest; Jeph Herrin; Pamela R Soulos; Roy H Decker; Lynn Tanoue; Gaetane Michaud; Anthony W Kim; Frank Detterbeck; Daniel Morgensztern; Cary P Gross
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.